Akouos, Inc.
Clinical trials sponsored by Akouos, Inc., explained in plain language.
Develops gene therapies for hearing loss and inner ear disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene therapy for ear tumors: Long-Term safety under review
Disease control By invitation onlyThis study follows 100 people with vestibular schwannoma (a non-cancerous ear tumor) who previously received a gene therapy called AAVAnc80-antiVEGF. Researchers will monitor for late side effects and measure tumor size changes over time using MRI scans. The goal is to understand…
Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene therapy for deafness: researchers track long-term safety and hearing gains
Disease control By invitation onlyThis study follows 30 people who previously received a gene therapy (AAVAnc80-hOTOF) for hearing loss caused by otoferlin gene mutations. Researchers will monitor safety over the long term, checking for late side effects, and measure hearing improvements using brain response test…
Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC